New credit for AMT
Amsterdam Molecular Therapeutics (AMT) will receive an Innovation Credit of up to 4 million euro.
SenterNovem has granted the credit to support the development of AMT’s gene therapy treatment for Duchenne Muscular Dystrophy. The credit will fund 35% of the program costs during the period to mid-2013. In December 2009 AMT also successfully raised 5 million euro of new funds via a private placement of convertible bonds.
